Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura J Esserman

Showing results (231-240 of 308) with videos related to

Pageof 31
Sort By:
Radiology|December 2, 2015
Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIALNola M Hylton, Constantine A Gatsonis, Mark A Rosen, et al.
AJR. American Journal of Roentgenology|May 1, 2018
MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 TrialJohn R Scheel, Eunhee Kim, Savannah C Partridge, et al.
NPJ Breast Cancer|August 4, 2021
Elevated risk thresholds predict endocrine risk-reducing medication use in the Athena screening registryYash S Huilgol, Holly Keane, Yiwey Shieh, et al.
Breast Cancer Research and Treatment|September 11, 2012
Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancerEsther H Lips, Rita A Mukhtar, Christina Yau, et al.
Tomography (Ann Arbor, Mich.)|March 26, 2025
MRI-Based Model for Personalizing Neoadjuvant Treatment in Breast CancerWen Li, Natsuko Onishi, Jessica E Gibbs, et al.
Biorxiv : the Preprint Server for Biology|September 5, 2025
Organoid-evaluable clinical biomarkers predict drug responses and guide new breast cancer therapiesTam Binh V Bui, Denise M Wolf, Michael C Bruck, et al.
Contemporary Clinical Trials|September 18, 2024
Overcoming challenges in conducting early phase breast cancer prevention trials: Bazedoxifene and conjugated estrogens vs waitlist controlCarol J Fabian, Dinesh Pal Mudaranthakam, Byron Gajewski, et al.
Annals of Surgical Oncology|July 9, 2024
Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy: Results from the I-SPY2 Clinical TrialMara A Piltin, Peter Norwood, Velle Ladores, et al.
Radiology|September 5, 2018
Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter TrialSavannah C Partridge, Zheng Zhang, David C Newitt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2024
Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant ChemotherapyMark Jesus M Magbanua, Ziad Ahmed, Rosalyn W Sayaman, et al.
Pageof 31

Showing results (231-240 of 308) with videos related to

Sort By:
Pageof 31
Radiology|December 2, 2015
Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIALNola M Hylton, Constantine A Gatsonis, Mark A Rosen, et al.
AJR. American Journal of Roentgenology|May 1, 2018
MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 TrialJohn R Scheel, Eunhee Kim, Savannah C Partridge, et al.
NPJ Breast Cancer|August 4, 2021
Elevated risk thresholds predict endocrine risk-reducing medication use in the Athena screening registryYash S Huilgol, Holly Keane, Yiwey Shieh, et al.
Breast Cancer Research and Treatment|September 11, 2012
Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancerEsther H Lips, Rita A Mukhtar, Christina Yau, et al.
Tomography (Ann Arbor, Mich.)|March 26, 2025
MRI-Based Model for Personalizing Neoadjuvant Treatment in Breast CancerWen Li, Natsuko Onishi, Jessica E Gibbs, et al.
Biorxiv : the Preprint Server for Biology|September 5, 2025
Organoid-evaluable clinical biomarkers predict drug responses and guide new breast cancer therapiesTam Binh V Bui, Denise M Wolf, Michael C Bruck, et al.
Contemporary Clinical Trials|September 18, 2024
Overcoming challenges in conducting early phase breast cancer prevention trials: Bazedoxifene and conjugated estrogens vs waitlist controlCarol J Fabian, Dinesh Pal Mudaranthakam, Byron Gajewski, et al.
Annals of Surgical Oncology|July 9, 2024
Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy: Results from the I-SPY2 Clinical TrialMara A Piltin, Peter Norwood, Velle Ladores, et al.
Radiology|September 5, 2018
Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter TrialSavannah C Partridge, Zheng Zhang, David C Newitt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2024
Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant ChemotherapyMark Jesus M Magbanua, Ziad Ahmed, Rosalyn W Sayaman, et al.
Pageof 31